Probiotics reduce acting out dreams
- Trial ID
- NCT06710574
- Official Title
- Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving Rapid Eye Movement Behavior Disorder with Parkinson's Disease
- Goal
- Probiotics reduce acting out dreams
- Phase
- PHASE4
- Status
- RECRUITING
- Sponsor
- Beijing Friendship Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 120 participants
- Conditions
- Parkinson Disease, Movement Disorders, Rapid Eye Movement Sleep Behavior Disorder, Gut Microbiomes, Magnetic Resonance Imaging (MRI), Probiotic
- Interventions
- PD-RBD, iRBD
Plain-Language Summary
The goal is to test whether taking specific probiotics can ease REM sleep behavior disorder symptoms in people with Parkinson's and in those with idiopathic RBD, and to learn how changing gut microbes might influence the brain. The approach gives probiotics containing Bifidobacterium triple viable and Bacillus licheniformis to shift the gut microbiome, which may reduce gut-driven inflammation and alter gut‑to‑brain signaling; researchers will track sleep and brain changes with polysomnography and MRI, and participants keep their Parkinson's meds stable since the probiotic is not a replacement for levodopa. They are looking for adults roughly 40 to 85 years old, including people with Parkinson's (Hoehn and Yahr stage 1,3) who have RBD, people with idiopathic RBD, and healthy controls, all with normal cognition, no recent probiotic or antibiotic use, and off clonazepam or melatonin before joining.
Locations
- Beijing Friendship Hospital, Capital Medical University, Beijing, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying PD-RBD. The goal is to test whether taking specific probiotics can ease REM sleep behavior disorder symptoms in people with Parkinson's and in those with idiopathic RBD, and to learn how changing gut microbes might influence the brain. The approach gives probiotics containing Bifidobacterium triple viable and Bacillus licheniformis to shift the gut microbiome, which may reduce gut-driven inflammation and alter gut‑to‑brain signaling; researchers will track sleep and brain changes with polysomnography and MRI, and participants keep their Parkinson's meds stable since the probiotic is not a replacement for levodopa. They are looking for adults roughly 40 to 85 years old, including people with Parkinson's (Hoehn and Yahr stage 1,3) who have RBD, people with idiopathic RBD, and healthy controls, all with normal cognition, no recent probiotic or antibiotic use, and off clonazepam or melatonin before joining.
- Who can participate?
- Participants must be between 40 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 4 trial is estimated to last approximately 2 years and 9 months.